Trial Profile
A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2021
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ALLEVIAD
- Sponsors MedImmune
- 28 Dec 2020 Data from 7 studies (NCT00757042, NCT00972179, NCT01405963, NCT01913028, NCT02512900, NCT02525094 & NCT02054130) was used to develop a population PK model to guide tezepelumab dose selection for phase III trials in patients with severe asthma, published in the Journal of Clinical Pharmacology.
- 11 Dec 2018 Results published in the Journal of the American Academy of Dermatology
- 19 Sep 2016 Status changed from active, no longer recruiting to completed.